Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

60.68
-0.5800-0.95%
Post-market: 60.680.00000.00%16:36 EDT
Volume:1.37M
Turnover:83.19M
Market Cap:11.74B
PE:404.53
High:61.64
Open:61.55
Low:60.24
Close:61.26
Loading ...

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients With Prurigo Nodularis (Pn) at 2025 American Academy of Dermatology Annual Meeting

THOMSON REUTERS
·
08 Mar

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Business Wire
·
08 Mar

Moody’s, Chubb, Incyte, Five9, CME: Insider Sales Surge

TIPRANKS
·
08 Mar

Incyte’s EVP Makes a Notable Stock Sale

TIPRANKS
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Teva Pharmaceutical (TEVA) and Incyte (INCY)

TIPRANKS
·
06 Mar

Incyte Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
04 Mar

EDSA: Raises $15 Million to Advance EB06…

Zacks Small Cap Research
·
03 Mar

Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?

Insider Monkey
·
02 Mar

Incyte’s Top Executive Makes a Major Stock Move!

TIPRANKS
·
01 Mar

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Business Wire
·
28 Feb

High Growth Tech Stocks to Watch in US Market February 2025

Simply Wall St.
·
28 Feb

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
28 Feb

Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery

Insider Monkey
·
25 Feb

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
25 Feb

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
22 Feb

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
19 Feb